GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » RP Bio lnc (XKRX:314140) » Definitions » Net Income From Continuing Operations

RP Bio lnc (XKRX:314140) Net Income From Continuing Operations : ₩4,369 Mil (TTM As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is RP Bio lnc Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. RP Bio lnc's net income from continuing operations for the three months ended in Mar. 2024 was ₩-518 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Mar. 2024 was ₩4,369 Mil.

RP Bio lnc Net Income From Continuing Operations Historical Data

The historical data trend for RP Bio lnc's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RP Bio lnc Net Income From Continuing Operations Chart

RP Bio lnc Annual Data
Trend Dec19 Dec20 Dec21 Dec22
Net Income From Continuing Operations
2,864.40 4,615.51 3,812.56 4,315.65

RP Bio lnc Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Net Income From Continuing Operations Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 550.15 2,102.00 3,250.69 -465.58 -518.07

RP Bio lnc Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩4,369 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

RP Bio lnc (XKRX:314140) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » RP Bio lnc (XKRX:314140) » Definitions » Net Income From Continuing Operations
Comparable Companies
XKRX:041910 XKRX:000220 XKRX:204840 XKRX:017180 XKRX:131030 XKRX:012790 XKRX:175250 XKRX:318010 XKRX:239610 XKRX:034940 ZTS XTER:MRK TSE:4502 LSE:HLN NSE:SUNPHARMA TSE:4523 TSE:4507 SZSE:000538 XSWX:SDZ HKSE:03692
Traded in Other Exchanges
N/A
Address
634, Samseong-ro, Gangnam-gu, Seoul, KOR, 06084
Website
http://www.rpskorea.com
RP Bio lnc is engaged in the pharmaceutical manufacturing business. It produces softgels, finished drugs, and other products.

RP Bio lnc (XKRX:314140) Headlines

No Headlines